Results 141 to 150 of about 644,370 (183)
Some of the next articles are maybe not open access.
The Journal of Steroid Biochemistry and Molecular Biology, 2007
In patients with hormone receptor positive DCIS tamoxifen reduces recurrence rates by almost 50%. Few data are available with aromatase inhibitors from randomised studies. In the ATAC study there were three DCIS lesions in the anastrozole arm and four in the tamoxifen arm in the women with ER positive invasive cancer. In the MA17 study which randomised
J Michael, Dixon +9 more
openaire +2 more sources
In patients with hormone receptor positive DCIS tamoxifen reduces recurrence rates by almost 50%. Few data are available with aromatase inhibitors from randomised studies. In the ATAC study there were three DCIS lesions in the anastrozole arm and four in the tamoxifen arm in the women with ER positive invasive cancer. In the MA17 study which randomised
J Michael, Dixon +9 more
openaire +2 more sources
Aromatase, Aromatase Inhibitors, and Breast Cancer
American Journal of Therapeutics, 2001Estrogens are involved in numerous physiologic processes and have crucial roles in particular disease states, such as mammary carcinomas. Estradiol, the most potent endogenous estrogen, is biosynthesized from androgens by the cytochrome P-450 enzyme complex called aromatase.
openaire +2 more sources
American Journal of Clinical Oncology, 1995
To review the aromatase inhibitors with emphasis on the newer agents that are being developed for the treatment of metastatic breast cancer. Review of English literature over the past 5 years using Med-Line and Cancer-Line computer search. All pertinent articles were included for this review.
N K, Ibrahim, A U, Buzdar
openaire +2 more sources
To review the aromatase inhibitors with emphasis on the newer agents that are being developed for the treatment of metastatic breast cancer. Review of English literature over the past 5 years using Med-Line and Cancer-Line computer search. All pertinent articles were included for this review.
N K, Ibrahim, A U, Buzdar
openaire +2 more sources
Inhibition of Aromatase in Vitro and in Vivo by Aromatase Inhibitors
Journal of Enzyme Inhibition, 1990(1990). Inhibition of Aromatase in Vitro and in Vivo by Aromatase Inhibitors. Journal of Enzyme Inhibition: Vol. 4, No. 2, pp. 179-186.
A S, Bhatnagar +2 more
openaire +2 more sources
Aromatase inhibitors and teratogenesis
Fertility and Sterility, 2004letter to the ...
openaire +2 more sources
The Journal of Steroid Biochemistry and Molecular Biology, 2007
The decrease in estrogen levels with the use of aromatase inhibitors results in an increase in the rate of bone remodelling. This result in an acceleration of bone loss, and probably to an increase in the risk of fractures. The risk of fracture is particularly high in the older woman and in the woman with a low bone mineral density. We have a number of
openaire +2 more sources
The decrease in estrogen levels with the use of aromatase inhibitors results in an increase in the rate of bone remodelling. This result in an acceleration of bone loss, and probably to an increase in the risk of fractures. The risk of fracture is particularly high in the older woman and in the woman with a low bone mineral density. We have a number of
openaire +2 more sources
Expert Opinion on Therapeutic Patents, 2002
Endocrine treatment is at the core of therapies against early and advanced breast cancer. Modulators of the estrogen receptor have monopolized the field, offering durable clinical responses with an excellent tolerability profile. The benefits of endocrine therapy, however, are limited to estrogen receptor positive patients.
Simonida Grubjesic +2 more
openaire +2 more sources
Endocrine treatment is at the core of therapies against early and advanced breast cancer. Modulators of the estrogen receptor have monopolized the field, offering durable clinical responses with an excellent tolerability profile. The benefits of endocrine therapy, however, are limited to estrogen receptor positive patients.
Simonida Grubjesic +2 more
openaire +2 more sources
Aromatase inhibitors—Socioeconomical issues
The Journal of Steroid Biochemistry and Molecular Biology, 2005Novel, third-generation aromatase inhibitors are currently implemented for treatment of postmenopausal breast cancer in the metastatic and adjuvant setting and, potentially, for breast cancer prevention. Introduction of novel therapeutic strategies to large patient groups may add significant costs to health care budgets, forcing institutions to focus ...
Per E, Lønning, Jürgen, Geisler
openaire +3 more sources
Bulletin du cancer, 1999
Aromatase inhibitors used in breast cancer, are drugs that inhibit the transformation of androstenedione and testosterone, respectively in estradiol and estrone. Two classes have been described: steroidal inhibitors which act competitively and irreversibly and non steroidal inhibitors which block the P 450 cytochrome. The first one is aminoglutethimide
M L, Feutrie, J, Bonneterre
openaire +1 more source
Aromatase inhibitors used in breast cancer, are drugs that inhibit the transformation of androstenedione and testosterone, respectively in estradiol and estrone. Two classes have been described: steroidal inhibitors which act competitively and irreversibly and non steroidal inhibitors which block the P 450 cytochrome. The first one is aminoglutethimide
M L, Feutrie, J, Bonneterre
openaire +1 more source
Aromatase inhibitors ? mechanisms of steroidal inhibitors
Breast Cancer Research and Treatment, 1994Inhibition of aromatase has been an attractive approach for examining the roles of estrogen biosynthesis in various physiological or pathological processes. Effective aromatase inhibitors can serve as potential therapeutic agents for controlling estrogen-dependent diseases such as hormone-dependent breast cancer.
openaire +2 more sources